Affimed Appoints Shawn M. Leland as Chief Executive Officer

Core Viewpoint - Affimed N.V. has appointed Shawn M. Leland as the new Chief Executive Officer, succeeding Dr. Andreas Harstrick, who will remain as Chief Medical Officer. This leadership change is expected to drive the company's growth and corporate development strategy in the immuno-oncology sector [1][4]. Company Overview - Affimed is a clinical-stage immuno-oncology company focused on leveraging the innate immune system to combat cancer. The company has three active clinical programs that have demonstrated clinical proof of concept [4]. Leadership Background - Shawn M. Leland brings over 15 years of experience in the pharmaceutical and biotechnology industries, with a strong track record in advancing oncology assets and raising significant capital. His previous roles include Interim CEO at ForeBio and CEO of Elevation Oncology, where he raised over $200 million, including a $100 million IPO [2][3]. Strategic Vision - Leland expressed enthusiasm about leading Affimed, emphasizing the importance of the company's pipeline and the need for novel therapies to reach underserved patients. He aims to create value for shareholders by navigating the company through critical inflection points [4]. Transition Acknowledgment - The Chairman of Affimed's Supervisory Board, Dr. Thomas Hecht, acknowledged Dr. Harstrick's contributions as acting CEO, highlighting the company's strong position and readiness for future clinical developments [4].